New Fees Hit OTC Drug Makers for 2026
Published Date: 3/18/2026
Notice
Summary
Starting October 1, 2025, companies that make or submit requests for over-the-counter (OTC) drug products will pay new facility fees for fiscal year 2026. These fees help the FDA keep OTC drugs safe and effective. If you own or run an OTC drug facility, get ready for these updated charges that last through September 30, 2026.
Analyzed Economic Effects
5 provisions identified: 0 benefits, 3 costs, 2 mixed.
FY2026 OTC Facility Fee Amounts
If you own an OTC monograph drug manufacturing facility (MDF), you will be charged a facility fee of $19,188 for the period October 1, 2025 through September 30, 2026. If your facility is a contract manufacturing organization (CMO), the fee for FY2026 is $12,792 (two-thirds of the MDF fee).
Who Is Assessed Fees (Fee-Liability Window)
Facilities identified as OTC monograph drug facilities during the fee-liable period from January 1, 2025 through December 31, 2025 will be assessed an FY2026 facility fee. A full fee is assessed for each MDF and a reduced fee (two-thirds) is assessed for each CMO facility.
Which Facilities Are Exempt or Excluded
Facilities that ceased OTC monograph drug activities and updated their FDA registration to that effect before January 1, 2025 are exempt from FY2026 facility fees. Also excluded from being OTC monograph drug facilities (and thus not assessed fees) are facilities whose only activities are manufacture of active pharmaceutical ingredient (API), production of clinical research supplies, testing, or placement of outer overpackaging on already-final packaged products. By contrast, relabelers and repackagers are treated as fee-subject OTC monograph drug facilities.
Payment Timing, Methods, and Consequences
FY2026 facility fees are due on June 1, 2026 (the later of June 1 or the first business day after an appropriations Act) and invoices will be issued in April 2026. Payments must be in U.S. currency drawn on a U.S. bank and are accepted online via Pay.gov (ACH/eCheck) or credit card (credit card payments allowed only for balances under $25,000); full payments only (no partial online payments). Unpaid fees will be treated as claims of the U.S. Government and referred to collection.
Change in Fee Due Date Starting FY2027
OMUFA II transitions facility fee due dates so that, starting in FY2027, facility fees will be due the first business day in October; for FY2027 specifically, fees will be due in two equal installments on the first business day of October and the first business day of February. This changes the prior timing when fees were due in the third fiscal quarter (June).
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-10321 — Vaccines and Related Biological Products Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Safety and Effectiveness of MFLUSIVA (Influenza Vaccine, mRNA) Manufactured by Moderna TX Inc.
The FDA is holding a public meeting on June 18, 2026, to talk about the safety and effectiveness of MFLUSIVA, a new flu vaccine made by Moderna. Anyone can watch online and share their thoughts before June 17. This is a big deal for people who get flu shots and could affect how this vaccine is used and approved.
2026-10295 — M11 Clinical Electronic Structured Harmonised Protocol (CeSHarP); International Council for Harmonisation; Guidance for Industry; Availability
The FDA just released a new, easy-to-use digital guide called M11 CeSHarP to help everyone involved in clinical trials share and review study plans faster and clearer. This affects drug companies, researchers, and regulators worldwide by setting a global standard for how trial info is written and shared electronically. The new rules kick in now, aiming to save time and reduce confusion, with no direct cost but big efficiency gains.
2026-10277 — Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability
The FDA just released new draft guides to help drug makers design studies proving their generic drugs work like the originals. If you’re in the drug business, now’s your chance to share feedback by July 21, 2026, before these guides become final. These updates aim to speed up drug approvals, potentially saving time and money for companies and patients alike!
2026-10284 — Protein Efficiency Ratio Rat Bioassay Studies To Demonstrate That a New Infant Formula Supports the Quality Factor of Sufficient Biological Quality of Protein; Guidance for Industry; Availability
The FDA just released new guidance to help baby formula makers prove their products have good-quality protein using special rat studies. This update affects formula manufacturers and labs, making it easier and clearer to show their formulas meet nutrition standards. The guidance is effective now, helping companies avoid costly mistakes and speed up getting new formulas to market.
2026-10268 — Notice of Decision Not To Designate Hepatitis Delta Virus Diseases as an Addition to the Current List of Tropical Diseases in the Federal Food, Drug, and Cosmetic Act
The FDA decided not to add Hepatitis Delta Virus (HDV) to the list of tropical diseases because it doesn’t fully meet the rules about market size and who it affects. This means drug makers won’t get special priority review vouchers for HDV treatments right now. People working on HDV drugs should keep an eye out for future updates but won’t see changes or new incentives immediately.
2026-10190 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Patent Term Restoration; Due Diligence Petitions; Filing, Format, and Content of Petitions
The FDA is updating how companies ask for extra patent time when their new drugs or devices take a while to get approved. This affects drug and medical device makers who want to protect their inventions longer. Comments on these changes are open until June 22, 2026, and the update aims to keep the process clear without adding extra costs or delays.
Previous / Next Documents
Previous: 2026-05275 — Physicochemical and Structural (Q3) Characterization of Topical Drug Products Submitted in Abbreviated New Drug Applications; Guidance for Industry, Availability
The FDA just released new rules to help companies making generic skin creams and gels prove their products work the same as brand-name ones. If you submit these drug applications, you’ll need to show detailed info about your product’s makeup and structure to get approval. This update starts now and aims to speed up safe, affordable generics without extra costs.
Next: 2026-05277 — Hazardous Materials: Notice of Applications for New Special Permits
The Department of Transportation just announced new requests for special permits to safely move hazardous materials by trucks, trains, ships, and planes. Companies and anyone involved in shipping dangerous goods should check these applications and send comments by April 17, 2026. These permits could change how some hazardous materials are handled, possibly speeding up shipments or adding new safety rules without extra costs.